Federal IDR outcomes: Urology in New York
In 2023 Q1–2025 Q4, the provider or facility offer prevailed in 86.7% of 30 determined Federal IDR dispute line items for urology in New York.
Determined line items
30
2023 Q1–2025 Q4 · 0 split decisions excluded
Provider win rate
86.7%
n = 30 · 2023 Q1–2025 Q4
Median payment vs QPA
–
n = 27, below 30 · 2023 Q1–2025 Q4
Median days to decision
–
not pooled across years (CMS changed the definition in 2025)
Dollar amounts are not shown for specialty groups: the CMS QPA and Offers file, the only source of dollar figures, has no specialty field. See methodology.
By period
| Period | Line items | Win % | Median ×QPA | 25th–75th | Ratio n | Median days |
|---|---|---|---|---|---|---|
| 2025 Q1–Q4 | Fewer than 30 determined line items; not shown. | |||||
| 2024 Q1–Q4 | Fewer than 30 determined line items; not shown. | |||||
| 2023 Q1–Q4 | Fewer than 30 determined line items; not shown. | |||||
| 2023 Q1–2025 Q4 | 30 | 86.7% | – | – | 27 | not pooled |
Line items = determined dispute line items (n). Win rate excludes split decisions and includes default decisions. Ratio n = line items reporting a payment-to-QPA ratio. Days are business days as reported by CMS (2023–2024: from IDR entity assignment; 2025: from initiation) and are never pooled.
Most disputed CPT codes
No row has 30 or more determined line items in 2025 Q1–Q4.
Related: all specialties in New York · Urology in all states
FAQ
What is the Federal IDR provider win rate for urology in New York?
In 2023 Q1–2025 Q4, the provider or facility offer was selected in 86.7% of 30 determined dispute line items for urology in New York. Split decisions are excluded from the denominator and default decisions are included. Withdrawn, settled and ineligible disputes are not in the CMS data.